Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma

C. F. Verschraegen; S. S. Legha; E. M. Hersh; C. Plager; N. Papadopoulos; M. A. Burgess

doi:10.1016/S0959-8049(05)80351-X

Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma

C. F. Verschraegen, S. S. Legha, E. M. Hersh, C. Plager, N. Papadopoulos, M. A. Burgess

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous methanol extraction residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9-24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.

Original language	English (US)
Pages (from-to)	708-711
Number of pages	4
Journal	European Journal of Cancer
Volume	29
Issue number	5
DOIs	https://doi.org/10.1016/S0959-8049(05)80351-X
State	Published - 1993
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(05)80351-X

Cite this

Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma. / Verschraegen, C. F.; Legha, S. S.; Hersh, E. M.; Plager, C.; Papadopoulos, N.; Burgess, M. A.

In: European Journal of Cancer, Vol. 29, No. 5, 1993, p. 708-711.

Research output: Contribution to journal › Article › peer-review

@article{4874335989414f07ada7e87bc0be3d85,

title = "Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma",

abstract = "A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous methanol extraction residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9-24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.",

author = "Verschraegen, {C. F.} and Legha, {S. S.} and Hersh, {E. M.} and C. Plager and N. Papadopoulos and Burgess, {M. A.}",

note = "Funding Information: Acknowledgements--Supportedi n part by a grant from Itafian Association for Cancer Research (AIRC)",

year = "1993",

doi = "10.1016/S0959-8049(05)80351-X",

language = "English (US)",

volume = "29",

pages = "708--711",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma

AU - Verschraegen, C. F.

AU - Legha, S. S.

AU - Hersh, E. M.

AU - Plager, C.

AU - Papadopoulos, N.

AU - Burgess, M. A.

N1 - Funding Information: Acknowledgements--Supportedi n part by a grant from Itafian Association for Cancer Research (AIRC)

PY - 1993

Y1 - 1993

N2 - A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous methanol extraction residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9-24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.

AB - A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous methanol extraction residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9-24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0027394449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027394449&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(05)80351-X

DO - 10.1016/S0959-8049(05)80351-X

M3 - Article

C2 - 8471328

AN - SCOPUS:0027394449

VL - 29

SP - 708

EP - 711

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -

Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this